OR WAIT 15 SECS
Kancera’s drug candidate KAND567 will be developed as a capsule formulation for oral administration. Work will be performed at Recipharm’s development facility in Solna, Sweden.
Contract development and manufacturing organization (CDMO) Recipharm and Kancera, a company developing cancer therapy, have signed a contract for the development and manufacture of drug candidate KAND567. Kancera’s KAND567 works by blocking the Fractalkine system and has been shown in preclinical disease models to effectively counteract the onset of autoimmune disorders, as well as neuritis and pain associated with chemotherapy. KAND567 will be developed as a capsule formulation for oral administration.
Recipharm’s role in this collaboration will be to develop the preparation required for effective release of KAND567 from the capsules, as well as manufacturing the pharmaceutical product. The work will be performed at Recipharm’s development facility in Solna, Sweden.
Kancera's drug candidate KAND567 has been shown to be effective against inflammation and pain in multiple preclinical disease models. In healthy individuals, Fractalkine and its receptor, CX3CR1, regulate migration of immune cells from the blood capillary wall into areas where the immune system is needed. Cancer cells use the same system (CX3CR1 and Fractalkine) to invade healthy organs and form metastases. The presence of Fractalkine has been associated with a lack of effect of immuno-oncological drugs. Kancera is evaluating KAND567’s ability to stop tumor growth.